New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:05 EDTAGIOAgios Pharmaceuticals announces AG-221 orphan drug designation
Agios Pharmaceuticals announced that the U.S. Food and Drug Administration has granted the company orphan drug designation for AG-221 for treatment of patients with acute myelogenous leukemia. AG-221 is an oral IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH2 mutation.
News For AGIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:40 EDTAGIOAgios Pharmaceuticals initiates Phase 1/2 clinical trial of AG-221
Subscribe for More Information
07:06 EDTAGIOFierce Biotech to hold a breakfast meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use